BioWorld

Aug. 11, 2003

MGI Raises $156.2M Publicly To Fund Oncology Drugs, Purchases

MGI Pharma Inc. netted $146.6 million after selling more shares at a higher-than-projected price in a previously reported public offering.(BioWorld Today) Read More

Genentech, OSI Begin Phase II With Tarceva For Brain Cancer

Italian Cattle Breeders Clone First Horse; Next? Geldings For Equine Champions, Embryonic Stem Cells

Pfizer Joins Effort To Limit Sales Of Drugs From Canada

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...